Celecoxib Chemical Structure

Celecoxib Chemical Structure
Molecular Weight: 381.37

Validation & Quality Control

Customer Product Validation(2)

Quality Control & MSDS

Related Compound Libraries

COX Inhibitors with Unique Features

  • Pan COX inhibitor

    Naproxen Pan-COX inhibitor, COX-1, IC50=8.7 μM; COX-2, IC50=5.2 μM.

  • Most Potent COX Inhibitor

    Lornoxicam COX-1, IC50=5 nM; COX-2, IC50=8 nM.

  • FDA-approved COX Inhibitor

    Ibuprofen Approved by FDA for relieving pain, alleviating fever,and reducing inflammation.

  • Classic COX Inhibitor

    Ketorolac Non-selective COX inhibitor of COX-1 and COX-2 with IC50 of 1.23 μM and 3.50 μM, respectively.

Product Information

  • Compare COX Inhibitors
    Compare COX Products
  • Research Area

Product Description

Biological Activity

Description Celecoxib is a selective COX-2 inhibitor with IC50 of 40 nM in Sf9 cells.
Targets COX-2 [1]
(Sf9 cells)
IC50 40 nM
In vitro Celecoxib shows low sensitivity against COX-1 with IC50 of 15 μM. [1] Celecoxib shows an anti-proliferative effect on nasopharyngeal carcinoma (NPC) cell lines including HNE1 and CNE1-LMP1 with IC50 of 32.86 μM and 61.31 μM, respectively. [2]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
A549NV;mfmhWTnWwY4Tpc44hSXO|YYm=Mn\hNE4yNTNyIN88US=>MnnIOFghcA>?MXHpcoR2[2W|IFnDRW0uOSCneIDy[ZN{cW:wIH;uJIJwfGhicILveIVqdiCjbnSgcXJPSSCuZY\lcC=>NY\SNnJ[OjZ3MUOxO|I>
H460MmPZSpVv[3Srb36gRZN{[Xl?NWnl[ocxOC5zLUOwJO69VQ>?MYe0PEBpNV\Xc5p7cW6mdXPld{BKS0GPLUGg[ZhxemW|c3nvckBwdiCkb4ToJJBzd3SnaX6gZY5lKG2UTlGgcIV3\Wx?MojqNlY2OTNzN{K=
HKESC-2NXnHdVc{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYfCSZkxOjEEoN88US=>NWHHZo13PDkEoHlCpC=>MlHEd4lodmmoaXPhcpRtgSCrbnPy[YF{\XNidHjlJGlEPTEEoI\hcJVmeyCxZjDvfIFtcXCuYYTpcuKhNE\LNHkzPjR5NE[5Ny=>
CaES-17MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXXSN3pHOjEEoN88US=>MXK0POKhcMLiMV\zbYdvcW[rY3HueIx6KGmwY4LlZZNmeyC2aHWgTWM2OMLidnHseYV{KG:oIH;4ZYxqeGyjdHnuxsA>NE\oN5QzPjR5NE[5Ny=>
HKESC-2MmL5RZBweHSxc3nzJGF{e2G7NFHCVnMzOMLizszNM4L2SlQ5yqCqwrC=NH\EXVBz\WS3Y3XzJI95[WyrcHzheIlvNWmwZIXj[YQh[XCxcITvd4l{M3;3UVI3PDd2Nkmz
CaES-17MUfBdI9xfG:|aYOgRZN{[Xl?M1LQOlIxyqEQvF2=NFixPGo1QMLiaNMgM2XxdZJm\HWlZYOgc5hidGmybHH0bY4ucW6mdXPl[EBieG:ydH;zbZM>MXWyOlQ4PDZ7Mx?=
A549NVvpSI1UT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlzkOU0yPjBizszNNX\RPWFnPDkEoHlCpC=>MlG1SG1UVw>?NWnMVYVJUUN3ME2xOlMvPCEQvF2=NVvJbYJ[OjZ2NkS2OFM>
HCC827MoPZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NX;uZoJ3PS1zNkCg{txONYHLc2xnPDkEoHlCpC=>NXHsUINQTE2VTx?=NWLnUmt{UUN3ME22PU4zKM7:TR?=MV6yOlQ3PDZ2Mx?=
A549NVLadZM4SXCxcITvd4l{KEG|c3H5NWKxV3RyQDBiwsXNM2\0XlQ5yqCqwrC=MoTESG1UVw>?NFnWeFFqdmS3Y3XzJIFxd3C2b4Ppdy=>NFntWlAzPjR4NE[0Ny=>
HCC827NELsSplCeG:ydH;zbZMhSXO|YYm=M3LKSlgxKML3TR?=M2H1elQ5yqCqwrC=NHvvTGJFVVORNV;XVmJWcW6mdXPld{BieG:ydH;zbZM>NIXZVYczPjR4NE[0Ny=>
SGC-7901/DDPNFT1PJpHfW6ldHnvckBCe3OjeR?=NXLP[Gh2OTEEoNM1US=>NX:1RZg5OjRiaB?=NIDCTI9qdmirYnn0d{BkgWOub3;4fYdmdmG|ZT2yJIFv\CCSLXfsfYNweHKxdHXpckBmgHC{ZYPzbY9vMX2yOlQxPzZ3Mx?=
SGC-7901 NE\yT|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2nSTlI1yqCqwrC=MnGzTWM2OD1zMUWuNFgh|ryPM2npTlI3PDB5NkWz
SGC-7901/DDPNULxUWhET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGXyRXozPMLiaNMgMWTJR|UxRTN3LkS1JO69VQ>?NGr4VHgzPjRyN{[1Ny=>
SGC-7901/DDPM{HpWWFxd3C2b4Ppd{BCe3OjeR?=MYqxNOKhyrWPNIW5OI0zPCCqMUXpcoR2[2W|IHHwc5B1d3OrczDjc41jcW6nZDD3bZRpKHerdHigZ4l{eGyjdHnuNG\oNYozPjRyN{[1Ny=>
SGC-7901/DDPNYq1NGJwTnWwY4Tpc44hSXO|YYm=M1vPTlExyqEEtV2=MVmyOEBpM2LpUolvcGmkaYTzJJRp\SCneIDy[ZN{cW:wIH;mJHAu\2y7Y3;wdo91\WmwIITodo92\2hiYnzvZ4tqdmdiRWCyMEBidmRiaX7hZ5RqfmG2aX7nJHBMSSCjbnSgR3JGSsLiMorMNlY1ODd4NUO=
SGC-7901/DDPNVTRRWlwTnWwY4Tpc44hSXO|YYm=NXO2U4dpOTEEoNM1US=>NIqyc3YzPCCqNX74VZRT[2G3c3XzJIEhdWG{a3XkJIRm[3KnYYPlJIlvKHSqZTDs[ZZmdCCxZjDCZ4wuOiCycn;0[YlvMnrLNlY1ODd4NUO=
H357NUTvXFdDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWi3MlUwOTBizszNNWq1OpgzPDhiaB?=NH34RnJFVVORNIq0N2ZqdmirYnn0d{Bk\WyuIHfyc5d1cMLiY3;tZolv\WRid3n0bEBU[WK3dH;jcIF5M3rQblI3ODB7OEe0
TAFNEDn[lVHfW6ldHnvckBCe3OjeR?=M2LRUVExyqEEtV2=MXi3JIQ>MlraZYZn\WO2czDURWZ{KGGmaHXzbZZmKHC{b4DldpRq\XN?MXqyOVk5PzF{Nx?=
TAFM2j3WGZ2dmO2aX;uJGF{e2G7M{TVVFExyqEEtV2=NIi3eIg{OC1zMkCgcYlvNFfpRWJxd2:{bImgZYZn\WO2czDkRYt1KHCqb4PwbI9zgWyjdHnvckBkd26|ZYH1[Y51KHSxIFXHSkB{cWewYXzpcoc>NV7DPWZnOjV7OEexNlc>
TAFM{j1VWZ2dmO2aX;uJGF{e2G7NUP5PY9HOTEEoNM1US=>M4Ls[FQ5KGh?NVnnbHVOcW6lcnXhd4V{KEWJRmKgcXJPSSCjbnSgdJJwfGWrbjDlfJBz\XO|aX;uMX2yOVk5PzF{Nx?=
PANC-1MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NF;uOnEzOC94MD:xNFAh|ryPMmO0NlQwPDhxN{KgbC=>M1LLVIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZTDhcoQh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{M1GyclI2QTd|ME[y
PANC-1NIX6dW1HfW6ldHnvckBCe3OjeR?=MUSyNE83OC9zMECg{txONXnqXZFxOjRiaB?=MYPheJRmdnWjdIOgZ4VtdCCrbo\hd4lwdiCjbnSgcYloemG2aX;uJIlvKGFiY3;uZ4VvfHKjdHnvck1l\XCnbnTlcpQhdWGwbnXyxsA>M1zyXVI2QTd|ME[y
HeLa MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYGyNOKh|ryPwrC=Mn\1NlTDqGh?Ml;F[Y5p[W6lZYOgdoFlcWG2aX;uMYlv\HWlZXSgbY5pcWKrdHnvckBw\iClZXzsJJBzd2yrZnXyZZRqd25?NGHMU4gzPTd5MESyNy=>
SACC-83M{DYPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlXnNlDDqM7:TdMgMmTBNlTDqGh?NFTjcVhmdmijbnPld{Bz[WSrYYTpc44ucW6mdXPl[EBqdmirYnn0bY9vKG:oIHPlcIwheHKxbHnm[ZJifGmxbh?=NXT2eVdlOjV5N{C0NlM>
HeLa M3vESWFxd3C2b4Ppd{BCe3OjeR?=NXn1cZN6OjEEoN88UeKhM4i2flI1yqCqM3u4VIVvcGGwY3XzJJJi\GmjdHnvck1qdmS3Y3XkJIlvcGmkaYTpc44hd2ZiY3XscEBieG:ydH;zbZM>M4HrR|I2PzdyNEKz
SACC-83MkfTRZBweHSxc3nzJGF{e2G7NHTlWHkzOMLizszNxsA>NWDmTXZUOjUEoHi=Mk\y[Y5p[W6lZYOgdoFlcWG2aX;uMYlv\HWlZXSgbY5pcWKrdHnvckBw\iClZXzsJIFxd3C2b4Ppdy=>NGLBTnAzPTd5MESyNy=>
HeLa MV7GeY5kfGmxbjDBd5NigQ>?MmKxNlAwPDBxOECg{txOM{TVcVI1yqCqMkjYeZBz\We3bHH0d{BRXEWQIIDhdpRq[WyueTDifUBqdmirYnn0bY5oKFOyMTygZY5lKGGldHn2ZZRmeyCSVFXOJIFv\CCrbnHjeIl3[XSnczDBT3Q>NG\ldo8zPTd5MESyNy=>
SACC-83NXywTZFHTnWwY4Tpc44hSXO|YYm=M1S5U|IxNzRyL{iwJO69VQ>?NWnqdXV2OjUEoHi=Mn\4eZBz\We3bHH0d{BRXEWQIIDhdpRq[WyueTDifUBqdmirYnn0bY5oKFOyMTygZY5lKGGldHn2ZZRmeyCSVFXOJIFv\CCrbnHjeIl3[XSnczDBT3Q>NHe2UVYzPTd5MESyNy=>
HLCZ01M2\HWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M16yUFDjiJN4MNMgxtVOMn[yOFghcA>?NWfrR3pnTE2VTx?=M{nlZYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVzNYDidnVWOjV5MkS4PVk>
HLCZ01NUnlXG1VTnWwY4Tpc44hSXO|YYm=MkHrOFDDqM7:TR?=NFnTOJczPCCqMkS0SG1UVw>?MnnObY5kemWjc3XzJIFk[3WvdXzheIlwdiCxZjDHNE9IOS2yaHHz[UBk\WyuczDjc41jcW6nZDD3bZRpKEmITj5OtS=>M3HobVI2PzJ2OEm5
HLCZ01MYrBdI9xfG:|aYOgRZN{[Xl?NVvZNnlpPDEEoN88US=>MnvXNlQhcA>?NEn3bINFVVORMnS5[Y5p[W6lZYOgZZBweHSxc3nzJINwdWKrbnXkJJdqfGhiSV\OMe6yNWrwPFJnOjV5MkS4PVk>
HLCZ01NHu0PIhHfW6ldHnvckBCe3OjeR?=M2fzU|QxyqEQvF2=NIjiXYwzPCCqMY\EUXNQM3joUYlv[3KnYYPld{BVWkGLTDDlfJBz\XO|aX;uJINwdWKrbnXkJJdqfGhiSX70[ZJn\XKxbj5OtS=>NVLxd2hxOjV5MkS4PVk>
MGC803NGHTNGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkmwNE03OCEQvF2=MUe3NkBpNFvKSHVKSzVyPUS3MlI26oDLwsJihKk3NjR|IN88US=>M1T0bVI2PzBzM{e4
SGC7901MlnwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoW2NE03OCEQvF2=MWG3NkBpM{m2VWlEPTB;NEOuOVPjiIoEsfMAjVUvOTJizszNMkfHNlU4ODF|N{i=
MGC803NIXi[HZHfW6ldHnvckBCe3OjeR?=NVXaV4l7PDEEoN88US=>M{jOPVgwOTZxMkSgbC=>NXS1NIZpfXC{ZXf1cIF1eyCFYnytZkBmgHC{ZYPzbY9vMkD4NlU4ODF|N{i=
SGC7901NVjyXpFUTnWwY4Tpc44hSXO|YYm=MoXEOFDDqM7:TR?=MXi4M|E3NzJ2IHi=MkPheZBz\We3bHH0d{BE[mxvYjDlfJBz\XO|aX;uM3\1N|I2PzBzM{e4
MCF-7 MnHPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHzTPXcyNzFyIN88US=>MVK3NkBpNITrXZhFVVORNYPPNIRz\W6qYX7j[ZMh[2GuY3n0dolwdC2rbnT1Z4VlKGOnbHyg[5Jwf3SqIHnubIljcXSrb36=NXniRnlQOjV4Nke1NVA>
MDA-MB-231 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1H4SlEwOTBizszNNGewVpI4OiCqNGXxelFFVVORMVTlcohidmOnczDjZYxkcXS{aX;sMYlv\HWlZXSgZ4VtdCCpcn;3eIghcW6qaXLpeIlwdg>?MlnUNlU3Pjd3MUC=
MDA-MB-231M3;zNWZ2dmO2aX;uJGF{e2G7NXvLN4VjOC12MDFCuW0>M1vjRVQuOjRiaB?=NGXRWZJqdmO{ZXHz[ZMhS0:[LUKgdJJwfGWrbjDlfJBz\XO|aX;uJIlvKGKxdHigeIlu\SCjbnSg[I9{\SCmZYDlcoRmdnRibXHucoVzNUjzO|ljOjV3OEezNlk>
MCF-7Ml3iSpVv[3Srb36gRZN{[Xl?MV6wMVQxKML3TR?=M{jSd|QuOjRiaB?=NUn6[G41\W6qYX7j[ZMhfGinIHXm[oVkfHNib3[gWHBCKG:wIFHCR2czKGW6cILld5Nqd28EoB?=NV;UcGtzOjV3OEezNlk>
MCF7-MX NH3L[mxHfW6ldHnvckBCe3OjeR?=NVTJV3U3OC12MDFCuW0>NEnYZYc1NTJ2IHi=M4j1TYVvcGGwY3XzJJRp\SCnZn\lZ5R{KG:oIGTQRUBwdiCDQlPHNkBmgHC{ZYPzbY9vyqB?M3zMe|I2PTh5M{K5
MDA-MB-231Mn65SpVv[3Srb36gRZN{[Xl?MlzRNE01OCEEtV2=NX7jfJN3PC1{NDDoNHPCR45{fGmvdXzheIV{KHSqZTDlfJBz\XO|aX;uJI9nKEGEQ1eyJJVxKHSxIESuNlchfGmvZYOgeI8h[2:wdILvcEBt\X[nbDDifUAyOiCqwrC=NH\VUpYzPTV6N{OyPS=>
A2780M2G3fWZ2dmO2aX;uJGF{e2G7M{Dxc|UwOTBxMUWg{txOMorkOFghcA>?NFrvNHRl\WO{ZXHz[ZMhS2:6LUKg[ZhxemW|c3nvckBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=>MWGyOVQzPDh7OB?=
SKOV3 M3jGdmZ2dmO2aX;uJGF{e2G7NV;BbZFbPS9zMD:xOUDPxE1?NFLEeHE1QCCqNWX3cldP\GWlcnXhd4V{KEOxeD2yJIV5eHKnc4Ppc44hcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI>NHWxb2wzPTR{NEi5PC=>
A2780MVzGeY5kfGmxbjDBd5NigQ>?MUe1M|ExNzF3IN88US=>MUC0PEBpMojF[YxmfmG2ZYOgeIhmKGW6cILld5Nqd25ib3[gSU1k[WSqZYLpckBidmRia3XyZZRqdg>?NUTZRXVEOjV2MkS4PVg>
SKOV3 MmXRSpVv[3Srb36gRZN{[Xl?MnzPOU8yOC9zNTFOwG0>NVLSZVdXPDhiaB?=Mofx[YxmfmG2ZYOgeIhmKGW6cILld5Nqd25ib3[gSU1k[WSqZYLpckBidmRia3XyZZRqdg>?Mn;UNlU1OjR6OUi=
A2780Mm\6SpVv[3Srb36gRZN{[Xl?MnTKOU8yOC9zNTFOwG0>MVS0PEBpMWfk[YNz\WG|ZYOgeIhmKGW6cILld5Nqd25ib3[gUk1k[WSqZYLpckBidmRiVnnt[Y51cW5?NHThdJUzPTR{NEi5PC=>
SKOV3 M3vvNWZ2dmO2aX;uJGF{e2G7M3;ZSFUwOTBxMUWg{txOMVq0PEBpMYjk[YNz\WG|ZYOgeIhmKGW6cILld5Nqd25ib3[gUk1k[WSqZYLpckBidmRiVnnt[Y51cW5?M1vvV|I2PDJ2OEm4
A2780NGjmSpFHfW6ldHnvckBCe3OjeR?=NFvwUGg2NzFyL{G1JO69VQ>?MmjPNUBpNH;NT3BqdmO{ZXHz[ZMhfGinIHX4dJJme3Orb36gc4YheC2DS2SgZY5lKHBvRWLLJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXyNYflb5ROOjV2MkS4PVg>
SKOV3 MmW1SpVv[3Srb36gRZN{[Xl?NETTOlQ2NzFyL{G1JO69VQ>?MkG0NUBpNUWxTHcxcW6lcnXhd4V{KHSqZTDlfJBz\XO|aX;uJI9nKHBvQVvUJIFv\CCyLVXST{BqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=>NEex[2QzPTR{NEi5PC=>
HCT-15MnHDSpVv[3Srb36gRZN{[Xl?M{PM[FExNTVyIN88US=>M3X4d|YuOzZiaB?=NWjxV2tEcW6mdXPld{B1cGViZYjwdoV{e2mxbjDv[kBEV1hvMjDpckBjd3SqIHTvd4Uh[W6mIITpcYUh\GWyZX7k[Y51KG2jbn7ldi=>NVHMU446OjV{MUiwNlg>
HT-29 Ml7FSpVv[3Srb36gRZN{[Xl?NWfSVI92OTBvNUCg{txOMnvaOk0{PiCqMkiwbY5lfWOnczD0bIUh\XiycnXzd4lwdiCxZjDDU3guOiCrbjDic5RpKGSxc3WgZY5lKHSrbXWg[IVx\W6mZX70JI1idm6nch?=MYiyOVIyQDB{OB?=
HSC3 MnTiR4VtdCCYaXHibYxqfHliQYPzZZk>MkTZNQKBmzRyIN88US=>NHXU[Wg1QCCqM{K1cGlEPTB;MkWuOeKyOS55OECg{txOM4XENlI2OTl6N{i5
HSC3 NYPRdlhSSXCxcITvd4l{KEG|c3H5MWWyOUDPxE1?Mn;nOFghcA>?NFrkdpZqdmS3Y3XzJIFxd3C2b4Ppdy=>MnvYNlUyQTh5OEm=
HSC3 MYHGeY5kfGmxbjDBd5NigQ>?Mm\SNlUh|ryPM4XFVVQ5KGh?M3WxeYV5cGmkaYTzJJNq\26rZnnjZY51dHlicnXkeYNm\CCvaXfyZZRqd25iY3;tZolv\WRid3n0bEBETVR?NU\zbpEzOjVzOUi3PFk>
HSC3 Mlj2SpVv[3Srb36gRZN{[Xl?MXyyOUDPxE1?MV20PEBpNHWyboNqdmirYnn0d{BJW0N|IHPlcIwhcW64YYPpc44h[2:vYnnu[YQhf2m2aDDDSXQ>M17mNVI2OTl6N{i5
HSC3 M{W2U2Z2dmO2aX;uJGF{e2G7NWKxfndiOjVizszNNF3sd3Y4OiCqMkXV[IVkemWjc3XzJG1OWC1{IHHu[EBOVVBvOTDwdo91\Wmwc9MgMk\UNlUyQTh5OEm=
201T M3rPO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoDJO|IhcA>?MnO1SG1UVw>?NUHWcHo5UUN3ME20PE43KML3TR?=NXrkelNlOjVyNUe5OFE>
273TNWXNXo1zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mn7uO|IhcA>?M1vXPGROW09?NYO5fWhSUUN3ME24NE42KML3TR?=MorrNlUxPTd7NEG=
Hep-2MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkXuN|AwPTBxMUCwJO69VQ>?MUmxNk8zPC9|Nj:0PEBpNXLhc3o{TE2VTx?=MnLpbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nIHHu[EBld3OnIHTldIVv\GWwdDDtZY5v\XJ?NXvINpdrOjR7OUi1OlQ>
Hep-2NXu1fVdjSXCxcITvd4l{KEG|c3H5MmTUOVAh|ryPNEXSbpkxNTR6IHi=M4\GRWROW09?MV\pcoR2[2W|IHHwc5B1d3OrczDpckBiKHSrbXWg[IVx\W6mZX70JI1idm6nch?=MXOyOFk6QDV4NB?=
Hep-2Ml2xSpVv[3Srb36gRZN{[Xl?NHPBNoE2OCEQvF2=NYewZm1bOC12ODDoM{TTc2ROW09?M{fibpJm\HWlZYOgeIhmKHSnbH;t[ZJie2ViYXP0bZZqfHliZ4Lh[JVidGy7NGXORZEzPDl7OEW2OC=>
Hep-2NES4d3pHfW6ldHnvckBCe3OjeR?=M4XKNVUxKM7:TR?=NXvCOXY3OC12ODDoM3zwdmROW09?NHvSNmZl\WO{ZXHz[ZMhfGinIH3SUmEh\XiycnXzd4lwdiCxZjDoWGVTXA>?NVHQR2dzOjR7OUi1OlQ>
SGC-7901MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWG0TmpbOTBxNUCvNVAxKM7:TR?=M1rBfFI1NzR6L{eyJIg>MnHySG1UVw>?M1jOb4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZTDhcoQh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{M3zwNlI1QTl{OUW4
MKN-45NH22TGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3GycVExNzVyL{GwNEDPxE1?MUSyOE81QC95MjDoNEizNY9FVVORNVTNXmtscW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCC2aX3lJIFv\CCmb4PlJIRmeGWwZHXueEBu[W6wZYK=NVnFXlBkOjR7OUK5OVg>
SGC-7901NXu3S5B3TnWwY4Tpc44hSXO|YYm=MluxNVAwPTBxMUCwJO69VQ>?NHTKT5Y1QCCqM4\NVGROW09?NF7tNlVld3ewcnXneYxifGW|IITo[UBuWk6DIHX4dJJme3Orb36gcIV3\Wy|IH;mJGNQYC1{IHHu[EBRS06DIHnuJIEh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{M4ryNVI1QTl{OUW4
MKN-45NHzwUWpHfW6ldHnvckBCe3OjeR?=MVyxNE82OC9zMECg{txONFLJfZI1QCCqM2HGV2ROW09?NFvpOo5ld3ewcnXneYxifGW|IITo[UBuWk6DIHX4dJJme3Orb36gcIV3\Wy|IH;mJGNQYC1{IHHu[EBRS06DIHnuJIEh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{MUOyOFk6Ojl3OB?=
C666-1MmPyR5l1d3SxeHnjbZR6KEG|c3H5MVGyNE05OCEQvF2=NH3pZ|czPCCqMoTt[IVkemWjc3XzJINwdG:weTDmc5Ju[XSrb36gbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYNCpC=>NUns[VhxOjR6NUS4N|g>
CNE-1MUPDfZRwfG:6aXPpeJkhSXO|YYm=M1HRRVIxNThyIN88US=>NGTxS|UzPCCqM37EXIRm[3KnYYPld{Bkd2yxbomg[o9zdWG2aX;uJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXyxsA>NHzReJIzPDh3NEizPC=>
CNE-2NXm3NGFqS3m2b4TvfIlkcXS7IFHzd4F6NWTCOVJSOjBvOECg{txOM2TqNFI1KGh?NWrEUZdn\GWlcnXhd4V{KGOxbH;ufUBnd3KvYYTpc44hcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZLDqA>?M3T6O|I1QDV2OEO4
C666-1NGX0c3BEgXSxdH;4bYNqfHliQYPzZZk>NV\G[4hLPjBizszNMlvRO{BlNID4TnFmdmijbnPld{Bz[WSrYYTpc44h[3m2b4TvfIlkcXS7IITodo92\2hiQ1;YMVIu\GWyZX7k[Y51KG2jbn7ldi=>NWi2XVl3OjR6NUS4N|g>
CNE-1NYj1WpBGS3m2b4TvfIlkcXS7IFHzd4F6NIXyTGc3OCEQvF2=MofoO{BlNED2NlVmdmijbnPld{Bz[WSrYYTpc44h[3m2b4TvfIlkcXS7IITodo92\2hiQ1;YMVIu\GWyZX7k[Y51KG2jbn7ldi=>NVy5[Gg1OjR6NUS4N|g>
SNU-1041Mmf1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHj4RoIxNTRyIN88US=>M3vVWlQ5KGh?NEDGN4NqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?=MkP0NlQ3QTJ5MEO=
SNU-1041NVXXOFFJTnWwY4Tpc44hSXO|YYm=NVWye3FkOjBxM{Cg{txOM4PBR|QhcA>?Ml;UbY5lfWOnczDlfJBz\XO|aX;uJI9nyqCFSF;QMEBIWlB5ONMgZY5lyqC[QmCxxsBifCC2aHWgVm5CKGyndnXsxsA>NYXGOYxIOjR4OUK3NFM>
SNU-1041NYrvVpdTTnWwY4Tpc44hSXO|YYm=NU\nPXF2OC12MDFOwG0>NH\HVHY1KGh?M1jPdZVxNXKnZ4XsZZRmeyCFSF;QxsBi\nSncjD0doVifG2nboSge4l1cCCqaXfoJINwdmOnboTyZZRqd26|NETxT3czPDZ7MkewNy=>
SGC-7901NXjPc25oT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkD5OVAuOTJ3IN88US=>MnP6NlQwPDhxN{KgbC=>NIqyN2pqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWgZY5lKGSxc3Wg[IVx\W6mZX70JI1idm6nch?=MnnDNlQ3PzZ|OUS=
SGC-7901MkDKRZBweHSxc3nzJGF{e2G7MmXLNVAxKM7:TR?=M{jOSVczKGh?MYfpcoR2[2W|IHHwc5B1d3Orcx?=M1P1N|I1Pjd4M{m0
SGC-7901M4HacGZ2dmO2aX;uJGF{e2G7M{jvO|c2NzFyMD:xNlUh|ryPM3rEXVI1NzR6L{eyJIg>NF;iRlRqdmO{ZXHz[ZMh[2G|cHHz[U05KGGwZDCtPUBuWk6DIHX4dJJme3Orb36gbY4h[m:2aDD0bY1mKGGwZDDkc5NmKG2jbn7ldi=>MnTHNlQ3PzZ|OUS=
LMeC MmThSpVv[3Srb36gRZN{[Xl?MorlNlAwPTBizszNMVi0PEBpNF\XWItl\WO{ZXHz[ZMhfGinIHX4dJJme3Orb36gc4YhS0:[LUKgdJJwfGWrbh?=M3rCWFI1PjV4N{S2
CMeC-1MkPiR4VtdCCYaXHibYxqfHliQYPzZZk>MYeyNE82OCEQvF2=M1PDeVQ5KGh?NHXKUFVqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?=MnLUNlQ3PTZ5NE[=
LMeCMmHnR4VtdCCYaXHibYxqfHliQYPzZZk>MUSyNE82OCEQvF2=MoHKOFghcA>?MlrabY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ?NWrNc|hVOjR4NU[3OFY>
CMeC-1M1K1cGZ2dmO2aX;uJGF{e2G7NFO3Z3QzOC93MDFOwG0>NYTTcWFoPDhiaB?=NGXFc49qdmS3Y3XzJGcyNVNiYYLy[ZN1MVeyOFY2Pjd2Nh?=
LMeCNEDvcWJHfW6ldHnvckBCe3OjeR?=NFvI[nEzOC93MDFOwG0>MXu0PEBpNY\PZ5BQcW6mdXPld{BIOS2VIHHydoV{fA>?M4q1eFI1PjV4N{S2
CMeC-1NYfwT5l5TnWwY4Tpc44hSXO|YYm=NVPm[WplOjBxNUCg{txOM{LPZVQ5KGh?NGXhS3dl\WO{ZXHz[ZMhfGinIHzleoVteyCxZjDjfYNtcW5iREGgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK=M1SwZ|I1PjV4N{S2
LMeCM3\v[WZ2dmO2aX;uJGF{e2G7NHHDWnMzOC93MDFOwG0>MnfqOFghcA>?NIK1SHdl\WO{ZXHz[ZMhfGinIHzleoVteyCxZjDjfYNtcW5iREGgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK=MXGyOFY2Pjd2Nh?=
CMeC-1NVvGfFh3TnWwY4Tpc44hSXO|YYm=MUeyNE82OCEQvF2=MWG0PEBpM4CzSolv\HWlZYOgZ4F{eGG|ZT2zJIFkfGm4YYTpc44>MYmyOFY2Pjd2Nh?=
LMeCMVnGeY5kfGmxbjDBd5NigQ>?NIrsVJEzOC93MDFOwG0>MkTMOFghcA>?NGDPdmRqdmS3Y3XzJINie3Cjc3WtN{Bi[3SrdnH0bY9vNWO0So4xOjR4NU[3OFY>
OVCAR-3NGXRb2hE\WyuIG\pZYJqdGm2eTDBd5NigQ>?MYOxNEDDvU1?NGfjNYUyKGh?M1;rSoVvcGGwY3XzJJBi[2yrdHH4[YwucW6mdXPl[EBwfmG{aXHuJINidmOncjDj[YxtKGSnYYToxsA>M1vaTVI1PTJyMkK3
OVCAR-3NVW2eoJKSXCxcITvd4l{KEG|c3H5M2XvRlExKML3TR?=MoDMNUBpNWTaXJdqeHKxbX;0[ZMheGGlbHn0ZZhmdC2rbnT1Z4VlKGGyb4D0c5Nqe8LiNUDh[YF3OjR3MkCyNlc>
OVCAR-3NYO0OpVrTnWwY4Tpc44hSXO|YYm=NH[wV44yOCEEtV2=NVe3V5BJOSCqNEPOVYlmdmijbnPld{Bx[WOuaYThfIVtNWmwZIXj[YQh[WO2aY\heIlwdiCxZjDjZZNx[XOnLUpCpC=>MXGyOFUzODJ{Nx?=
OVCAR-3NXnjTlN7TnWwY4Tpc44hSXO|YYm=NI\ENlYyOCEEtV2=NUfENYNtOSCqM4j4OoRwf25vcnXneYxifGW|IF7GMe67SiCjY4TpeoF1cW:wIHnu[JVk\WRiYomgdIFkdGm2YYjlcC=>M2Xle|I1PTJyMkK3
OVCAR-3NHS0boNHfW6ldHnvckBCe3OjeR?=NITweFgyOCEEtV2=NIj0ZlQyKGh?NFm1RY1qdmirYnn0d{Bx[WOuaYThfIVtNWmwZIXj[YQhSWu2IIDoc5NxcG:{eXzheIlwdg>?NIC4PZAzPDV{MEKyOy=>
CF33M4nTb2Z2dmO2aX;uJGF{e2G7MYWxNFAh|ryPMkXRNlQhcA>?M3joV4lv\HWlZYOg[I94dnKnZ4XsZZRqd25ib3[gR29ZNTJicILveIVqdiCneIDy[ZN{cW:wMnzNNlQ2ODN5OEK=
CF33MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHXmPFAyOC1zMECg{txOMYGwMVQh\A>?MmLxbY5pcWKrdIOgZ4VtdCCycn;sbYZmemG2aX;uJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXyMmrPNlQ2ODN5OEK=
CF33Mn;FSpVv[3Srb36gRZN{[Xl?MY[xNE0yODBizszNMl\LOE0zPCCqMnzB[IVkemWjc3XzJINmdGy|IHnuJJRp\SCVIIDoZZNmKGGwZDDpcoNz\WG|ZYOgZ4VtdHNiaX6gS|AwTzFiYYLy[ZN1MUiyOFUxOzd6Mh?=
LNCaPNIHUcYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUeyM|UwOTBizszNM3;XXVk3KGh?MXXpcohq[mm2czDj[YxtKGe{b4f0bEB{cWewaX\pZ4FvfGy7IHPvcYJqdmWmIIfpeIgh[XSxco\hd5RifGmwNXrQfJF4OjR{OU[5O|g>
LNCaPM1nhU2Fxd3C2b4Ppd{BCe3OjeR?=NVX6fI1zOi93L{GwJO69VQ>?MVm5OkBpMWnpcoR2[2W|IHHwc5B1d3OrczDjc41jcW6nZDD3bZRpKGG2b4L2ZZN1[XSrbh?=MWOyOFI6Pjl5OB?=
PC-3 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2jTd|AuPTBizszNMX[0PQKBkWh?NFLXVW1qdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>?Mk\rNlQyOjd6OEK=
PC-3 M1q4e2NmdGxiVnnhZoltcXS7IFHzd4F6NGPHNXoxNTFyMDFOwG0>NUGxOGZVPzJiaB?=NWHrXXNR\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[UBl\XCnbnTlcpQhdWGwbnXyNGfWU2kzPDF{N{i4Ni=>

... Click to View More Cell Line Experimental Data

In vivo Celecoxib exhibits a potent, oral anti-inflammatory activity. Celecoxib reduces acute inflammation in the carrageenan edema assay and chronic inflammation in the adjuvant arthritis model with ED50 of 7.1 mg/kg and 0.37 mg/kg/day, respectively. In addition, Celecoxib also exhibits analgesic activity in the Hargreaves hyperalgesia model with ED50 of 34.5 mg/kg. Besides, Celecoxib produces no acute GI toxicity in rats at doses up to 200 mg/kg and no chronic GI toxicity in rats at doses up to 600 mg/kg/day over 10 days. [1] In a C3Hf/KamLaw female mouse model, Celecoxib increases median survival time of 105 days (range, 79-145 days) after 13.5 Gy local thoracic irradiation (LTI) alone to 142 days (range, 94-155 days). [3]
Features

Protocol(Only for Reference)

Kinase Assay: [1]

COX enzyme assay in vitro Expression of COX protein in insect cells is determined by assessing PG-synthetic capability in homogenates from cells incubated for 3 days with COX-1 or COX-2 baculovirus. Cells expressing COX-1 or COX-2 are homogenized and incubated with arachidonic acid (10 μM). COX activity is determined by monitoring PG production. No COX activity is detected in mock-infected Sf9 cells. Celecoxib are preincubated with crude 1% CHAPS homogenates (2-10 μg of protein) for 10 minutes before addition of arachidonic acid. PGE2 formed is detected by ELISA after 10 minute incubation.

Cell Assay: [2]

Cell lines HNE1 and CNE1-LMP1
Concentrations 0-75 μM
Incubation Time 48 hours
Method The antiproliferative effect of Celecoxib on NPC cells is assessed using an MTT assay. Cells are seeded into 96-well plates and allowed to attach for 24 hours. The cells are then treated with increasing concentrations of Celecoxib (0 to 75 μM) dissolved in DMSO (final concentration ≤0.1%) and incubated for up to 48 hours. After the incubation, 20 μL of MTT dye (5 mg/mL) are added to each well and cells are incubated at 37 °C for 4 hours. After removing the supernatants, the crystals are dissolved in DMSO and the absorbance is measured at 490 nm. The half-maximal inhibitory concentration (IC50) values and the 95% confidence intervals are calculated using probit regression using SPSS 15.0 software. The experiment is performed in triplicate and repeated at least three times.

Animal Study: [1]

Animal Models A 0.1 mL aliquot of a 1% solution of carrageenan in 0.9% sterile saline or 1 mg of Mycobacterium butyricum in 50 μL of mineral oil is administered to the right hind foot pad of male Sprague−Dawley rats.
Formulation Celecoxib is dissolved in 0.5% methyl cellulose and 0.025% Tween-20.
Dosages ≤200 mg/kg
Administration Administered via p.o.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Penning TD, et al. J Med Chem, 1997, 40(9), 1347-1365.

[2] Liu DB, et al. Acta Pharmacol Sin, 2012, 33(5), 682-690.

view more

Clinical Trial Information( data from http://clinicaltrials.gov, updated on 2016-04-16)

NCT Number Recruitment Conditions Sponsor
/Collaborators
Start Date Phases
NCT02160301 Suspended Post Operative Pain Control University of North Carolina, Chapel Hill November 2017 Phase 4
NCT02703363 Not yet recruiting Depression|Bipolar Disorder|Bipolar Depression|Mood Disorders Pakistan Institute of Learning and Living|Dow University  ...more Pakistan Institute of Learning and Living|Dow University of Health Sciences|Abbasi Shaheed Hospital|Rawalpindi Medical College, Pakistan|University of Manchester|Stanley Medical Research Institute August 2016 Phase 3
NCT02726659 Not yet recruiting Bipolar Disorder|Postpartum Depression Lawson Health Research Institute May 2016 Phase 3
NCT02711579 Not yet recruiting Electrophysiologic Property of Brain Seoul National University Hospital April 2016 Phase 1
NCT02688400 Not yet recruiting Osteoarthritis|Osteoarthritis, Knee TRB Chemedica International SA|ArthroLab Inc. April 2016 Phase 3

view more

Chemical Information

Download Celecoxib SDF
Molecular Weight (MW) 381.37
Formula

C17H14F3N3O2S

CAS No. 169590-42-5
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms SC 58635
Solubility (25°C) * In vitro DMSO 76 mg/mL (199.28 mM)
Ethanol 33 mg/mL (86.53 mM)
Water <1 mg/mL (<1 mM)
In vivo 2% DMSO/30% PEG 300/5% Tween 80/ddH2O 5mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name 4-(5-p-tolyl-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide

Customer Product Validation (2)


Click to enlarge
Rating
Source Br J Pharmacol 2014 171(2), 498-508. Celecoxib purchased from Selleck
Method Metabolic evaluation
Cell Lines Wild-type and EC-AMPK mice
Concentrations 50 mg·kg−1 ·day−1
Incubation Time 4 weeks
Results The treatment with either drughad no effects on body weight and blood glucose levels(A), but significantly decreased the circulating triglyceride and cholesterol levels in EC-AMPK mice (B).

Click to enlarge
Rating
Source J Cell Physiol 2014 10.1002/jcp.24843. Celecoxib purchased from Selleck
Method Live-dead assay
Cell Lines HCC38 cells
Concentrations 5.0 uM
Incubation Time 24 h
Results Initial studies examined whether there was a toxic interaction between the PDE5 inhibitor sildenafil and the non-steroidal anti-inflammatory drug celecoxib. In mammary carcinoma cell lines growing in 10% fetal calf serum sildenafil and celecoxib interacted in a greater than additive fashion to kill parental wild type tumor cells as well as anoikis resistant variants of these cells.

Product Use Citation (6)

Tech Support & FAQs

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related COX Products

  • Xanthohumol

    Xanthohumol, a prenylated chalcone from hop, inhibits COX-1 and COX-2 activity and shows chemopreventive effects. Phase 1.

  • AZD3839

    AZD3839 is a potent and selective BACE1 inhibitor with Ki of 26.1 nM, about 14-fold selectivity over BACE2. Phase 1.

  • A-438079 HCl

    A-438079 HCl is a potent, and selective P2X7 receptor antagonist with pIC50 of 6.9.

  • Indomethacin

    Indomethacin is a nonselective COX1 and COX2 inhibitor with IC50 of 0.1 μg/mL and 5 μg/mL, respectively, used to reduce fever, pain, stiffness, and swelling.

  • Lornoxicam

    Lornoxicam is a non-steroidal COX-1/COX-2 inhibitor, used as an anti-inflammatory drug to treat pain, osteoarthritis, and rheumatoid arthritis.

  • Aspirin

    Aspirin is a salicylate, and irreversible COX1 and COX2 inhibitor, used as an analgesic to relieve minor aches and pains, as an antipyretic to reduce fever, and as an anti-inflammatory medication.

  • Rofecoxib

    Rofecoxib is a COX-2 inhibitor with IC50 of 18 nM.

  • Ketorolac

    Ketorolac (Ketorolac tromethamine) is a non-selective COX inhibitor of COX-1 and COX-2 with IC50 of 1.23 μM and 3.50 μM, respectively.

    Features:A COX-1 preferential inhibitor among currently marked nonsteroidal anti-inflammatory drugs (NSAIDs).

  • Bufexamac

    Bufexamac is a COX inhibitor for IFN-α release with EC50 of 8.9 μM.

    Features:A specific inhibitor of class IIB histone deacetylases.

  • Ibuprofen

    Ibuprofen (Dolgesic) is an anti-inflammatory inhibitor targeting COX-1 and COX-2 with IC50 of 13 μM and 370 μM, respectively.

    Features:Considered a core medicine in the WHO's "WHO Model List of Essential Medicines" (a list of the minimum medical requirements for a basic healthcare system).

Recently Viewed Items

Tags: buy Celecoxib | Celecoxib ic50 | Celecoxib price | Celecoxib cost | Celecoxib solubility dmso | Celecoxib purchase | Celecoxib manufacturer | Celecoxib research buy | Celecoxib order | Celecoxib mouse | Celecoxib chemical structure | Celecoxib mw | Celecoxib molecular weight | Celecoxib datasheet | Celecoxib supplier | Celecoxib in vitro | Celecoxib cell line | Celecoxib concentration | Celecoxib nmr
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us